Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi PharmaphorumThe FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.NeuroscienceRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) Pharmaphorum The FDA has cleared Eisai and Biogen’s Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits. Neuroscience Read full story Post navigation Previous: Cellares and Sonoma partner to automate cell therapy manufacturingNext: Novartis and Chai Discovery collaborate on antibody identification Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026